Insider Trading March 24, 2026

Darden Director Disposes $468K in Stock; Analysts Raise Targets After Modest Q3 Beat

Director Simon William S. sold 2,333 shares while Darden’s recent quarter topped estimates and multiple firms boosted price targets

By Nina Shah DRI
Darden Director Disposes $468K in Stock; Analysts Raise Targets After Modest Q3 Beat
DRI

A Darden Restaurants director executed a share sale worth $468,081 on March 23, 2026. The company posted a slight quarterly earnings beat and revenue marginally above expectations, prompting a string of analyst price-target increases and reiterated outperformance calls. Valuation metrics and InvestingPro’s Fair Value assessment present contrasting signals for investors.

Key Points

  • Director Simon William S. sold 2,333 shares on March 23, 2026 at $200.6351 per share for $468,081 and now directly owns 6,281 shares.
  • Darden reported fiscal Q3 2026 EPS that beat estimates by $0.01 and revenue of $3.35 billion, $12 million above expectations.
  • Several analysts increased price targets or reiterated positive ratings following results, with targets ranging from $220 to $240.

Simon William S., a member of the board of Darden Restaurants Inc (NYSE: DRI), sold 2,333 shares of the restaurant operator on March 23, 2026, at a per-share price of $200.6351. The transaction generated proceeds of $468,081. After the sale, Simon William S. retained direct ownership of 6,281 shares of Darden stock.

On valuation metrics, Darden carries a market capitalization of $23.12 billion and trades at a price-to-earnings ratio of 21.12. An InvestingPro analysis cited in company materials indicates the stock appears overvalued relative to its Fair Value. The firm also notes that DRI is included among more than 1,400 U.S. equities covered by InvestingPro’s Pro Research Reports.


Financial results for Darden’s fiscal third quarter of 2026 showed a narrow outperformance versus consensus forecasts. The company reported adjusted earnings per share that exceeded estimates by $0.01, while revenue came in at $3.35 billion, beating consensus by $12 million.

Following the quarterly results, a number of sell-side research shops adjusted their price targets and maintained or reiterated favorable ratings. Argus raised its price target to $240 and kept a Buy rating in place. Wolfe Research reaffirmed an Outperform rating with a $220 price objective, highlighting stronger-than-expected sales in February, particularly across the LongHorn Steakhouse and Fine Dining segments. Evercore ISI increased its price target to $230, citing market share gains and menu enhancements at Olive Garden. KeyBanc lifted its target to $226, calling out solid third-quarter performance and constructive guidance for the fourth quarter. Morgan Stanley maintained an Overweight stance with a $236 target, pointing to robust same-store sales and favorable fourth-quarter sales growth expectations.

Taken together, the analyst actions illustrate broad buy-side interest in Darden’s recent operational momentum and the market’s reaction to a modest earnings beat, even as valuation metrics and third-party Fair Value analysis suggest investors should weigh price levels carefully.


Summary of the insider transaction and related market context is straightforward: a director sale totaling $468,081, a company-level earnings and revenue beat by slim margins, and multiple firms adjusting their public price targets higher while maintaining positive or outperforming recommendations.

Risks

  • Valuation risk: InvestingPro’s analysis indicates Darden’s stock appears overvalued relative to its Fair Value, which may weigh on returns if market sentiment shifts.
  • Operational reliance on sustained sales momentum: Analyst upgrades cite stronger sales—particularly in LongHorn, Fine Dining and Olive Garden—so any slowdown in comparable sales could pressure forecasts.
  • Analyst expectations: Price-target increases reflect optimistic assumptions; if future quarters fail to meet these expectations the analyst consensus and share price could be vulnerable.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026